The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Atacicept Shows Promise in Lupus Treatment Trials

Atacicept Shows Promise in Lupus Treatment Trials

August 17, 2018 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Noting that atacicept may be a potent immunosuppressant and some serious infections and deaths have been reported in the past, Dr. Merrill emphasizes the current study guarded against the risk for serious infections by requiring all patients be up to date on their vaccinations. “Also, blood tests for levels of protective antibodies (immunoglobulins) were followed to mitigate the risk for infection during the study,” she says. Serious infections occurred in 1% of patients treated with atacicept 150 mg, 5.9% at 75 mg, and 5.0% with placebo. There were no deaths in this study.

You Might Also Like
  • Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data
  • Sifalimumab Shows Some Promise Against Lupus
  • J&J’s Stelara Shows Promise Against Lupus in Study
Explore This Issue
August 2018
Also By This Author
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis

Benefits

In exploratory analyses assessing SRI-4 in subgroups of patients, the study found a significant benefit with atacicept in patients with more clinically and serologically active disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Patients with serologically active disease treated with atacicept 75 mg and 150 mg had significantly higher SRI-4 response rates than placebo at 24 weeks (62.1% and 61.5%, respectively, vs. 24.1%; P=0.002). In addition, the study found significantly higher SRI-4 and SRI-6 response rates at 24 weeks in patients with high levels of clinical disease activity treated with atacicept 150 mg compared with placebo (62.7% vs. 42.3%; P=0.029).

Commenting on the study, Zahi Touma, MD, clinician-scientist and assistant professor at the University of Toronto, Toronto Lupus Clinic, Ontario, Canada, notes this is not the first trial to show the treatment effect size of a drug being evaluated (e.g., atacicept), compared with placebo, is larger in patients with more clinically active disease. Given that, “we should be more selective in lupus trials by mandating the severity level for disease activity,” he says.

Dr. Touma

Dr. Touma

Dr. Touma suggests mandating that patients enrolled in a clinical trial have active arthritis in six joints at baseline rather than two or more as defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SELDAI-2K).

The study also found a significant reduction in severe disease flares with atacicept at both doses compared with placebo (hazard ratio of 0.18, 95% CI 0.05-0.62; P=0.002). This was particularly seen in patients with high disease activity.

All things considered, Dr. Merrill says the findings “suggest that atacicept may have value for lupus patients and provide support for continued study of the treatment.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Touma agrees. “Despite this negative trial, I still think atacicept is a promising drug that requires further evaluation in phase 3 trials,” he says, adding that the success of future trials can be enhanced by accounting for the most common SLE-related obstacles in clinical trials, such as the lack of stringent discriminatory outcome measures, inadequate sample size and endpoints, excessive background therapy (glucocorticoids in particular) and the heterogenous nature of the sample population.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Drug Updates, SLE (Lupus) Tagged With: ataciceptIssue: August 2018

You Might Also Like:
  • Atacicept, Mavrilimumab Drug Updates, Trials, Safety Data
  • Sifalimumab Shows Some Promise Against Lupus
  • J&J’s Stelara Shows Promise Against Lupus in Study
  • Mesoblast Cell Treatment Shows Promise in Rheumatoid Arthritis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.